PMID-26924987 – Selank Affects GABAergic Neurotransmission Gene Expression
Volkova A et al., "Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission," Front Pharmacol, 2016;7:31.
Quick Reference
| Property | Value |
|---|---|
| PMID | 26924987 |
| DOI | 10.3389/fphar.2016.00031 |
| Year | 2016 |
| Journal | Frontiers in Pharmacology |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Rodent model (gene expression analysis) |
| Peptide(s) Studied | Selank |
Key Findings
- 45 neurotransmission-related genes were altered at 1 hour after Selank administration, with 22 genes still showing changes at 3 hours
- Positive correlation was observed between Selank treatment and GABA-related gene expression changes, suggesting a GABAergic mechanism of anxiolytic action
- Results suggest Selank acts via allosteric GABAergic modulation rather than direct benzodiazepine-like receptor binding
Study Design
Rodents received Selank administration and gene expression profiling was performed at 1-hour and 3-hour time points post-injection. Expression of genes involved in GABAergic neurotransmission was measured and compared to controls to characterize Selank's molecular mechanism of action.
Limitations
- Animal model — gene expression changes may not directly translate to human neurophysiology
- Limited time points assessed (1h and 3h only); longer-term expression changes not captured
Clinical Relevance
These findings provide a molecular basis for Selank's anxiolytic properties and support its classification as a GABAergic modulator with a potentially safer profile than classical benzodiazepines, given its allosteric rather than direct mechanism.
Related
#research #animal-in-vivo #evidence-level-V